Cargando…

Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

High tumor mutational burden (TMB-H) correlates with improved immunotherapy response. We assessed atezolizumab 1,200 mg every 3 weeks for TMB-H tumors from MyPathway (NCT02091141), a phase IIa multibasket study. One hundred twenty-one patients had advanced solid tumors with TMB ≥10 mut/Mb by any Cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friedman, Claire F., Hainsworth, John D., Kurzrock, Razelle, Spigel, David R., Burris, Howard A., Sweeney, Christopher J., Meric-Bernstam, Funda, Wang, Yong, Levy, Jonathan, Grindheim, Jessica, Shames, David S., Schulze, Katja, Patel, Arisha, Swanton, Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394388/ https://www.ncbi.nlm.nih.gov/pubmed/34876409 http://dx.doi.org/10.1158/2159-8290.CD-21-0450

Ejemplares similares

Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study
por: Kurzrock, R., et al.
Publicado: (2020)

Signature program: a platform of basket trials
por: Slosberg, Eric D., et al.
Publicado: (2018)

Challenges and perspective of drug repurposing strategies in early phase clinical trials
por: Kato, Shumei, et al.
Publicado: (2015)

Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm
por: Narita, Yusuke, et al.
Publicado: (2022)

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
por: Subbiah, Vivek, et al.
Publicado: (2020)

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
por: Agashe, Ruchi, et al.
Publicado: (2020)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden
por: Shemesh, Colby S., et al.
Publicado: (2020)

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
por: Kowanetz, Marcin, et al.
Publicado: (2018)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials
por: Livingston, J. Andrew, et al.
Publicado: (2016)

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening
por: Adashek, Jacob J., et al.
Publicado: (2021)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

Ploidy-Seq: inferring mutational chronology by sequencing polyploid tumor subpopulations
por: Malhotra, Ankit, et al.
Publicado: (2015)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

Tumor Lysis Syndrome: Introduction of a Cutaneous Variant and a New Classification System
por: Cohen, Philip R, et al.
Publicado: (2021)

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
por: Chaft, Jamie E., et al.
Publicado: (2022)

Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study
por: Subbiah, Vivek, et al.
Publicado: (2019)

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
por: Oaknin, Ana, et al.
Publicado: (2020)

High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting
por: Joshi, Rushikesh S., et al.
Publicado: (2022)

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
por: Kato, Shumei, et al.
Publicado: (2017)

BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease
por: Janku, Filip, et al.
Publicado: (2014)

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
por: Owusu-Brackett, Nicci, et al.
Publicado: (2020)

A Case Report of Atezolizumab Induced Tumor Lysis Syndrome
por: Fa’ak, Faisal, et al.
Publicado: (2019)

Tumor mutational burden is not predictive of cytotoxic chemotherapy response
por: Nikanjam, Mina, et al.
Publicado: (2020)

Basket Ball
Publicado: (1965)

Basket Ball
Publicado: (1965)

Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
por: Bieg‐Bourne, Cheyennedra C., et al.
Publicado: (2020)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
por: Tang, Chad, et al.
Publicado: (2013)

Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines
por: Yap, Timothy A., et al.
Publicado: (2022)

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patients
por: Nikanjam, Mina, et al.
Publicado: (2019)

Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real‐world precision‐medicine population
por: Rosenberg, Shai, et al.
Publicado: (2023)

Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples
por: Stewart, David J, et al.
Publicado: (2014)

Genomic landscape of salivary gland tumors
por: Kato, Shumei, et al.
Publicado: (2015)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2009)

Impacted and Fractured Biliary Basket: A Second Basket Rescue Technique
por: Benatta, Mohammed Amine, et al.
Publicado: (2016)

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial
por: Kim, Edward S., et al.
Publicado: (2022)

Activated autologous dendritic cells injected intratumorally are able to overcome local and systemic immune suppression imposed by the tumor and its microenvironment
por: Subbiah, Vivek, et al.
Publicado: (2014)

Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab
por: Iwai, Toshiki, et al.
Publicado: (2021)

Click chemistry, 3D-printing, and omics: the future of drug development
por: Kurzrock, Razelle, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r9mc1b17alffv7njhprfhkupav